Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal
Artelo Biosciences, Inc. (ARTL)
US:NASDAQ Investor Relations:
artelobio.com/investors
Company Research
Source: GlobeNewswire
LA JOLLA, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that positive non-clinical data with the Company’s Fatty Acid Binding Protein 5 (FABP5) inhibitor program under development in collaboration with The Research Foundation of the State University of New York Stony Brook, were published in the October 2019 issue of The Prostate, a premier peer-reviewed journal. (Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth, Carbonetti et. al, The Prostate, 2019, 1-11) Prostate cancer remains the second leading cause of cancer-related death among men. Taxanes, such as docetaxel and cabazitaxel are utilized in standard treatment regimens for chemotherapy naïve castration-resistant prostate cancers. However, tumors often develop resistance to taxanes, and taxane-t
Show less
Read more
Impact Snapshot
Event Time:
ARTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTL alerts
High impacting Artelo Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ARTL
News
- Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer TherapyGlobeNewswire
- Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern TimeGlobeNewswire
- Artelo Biosciences, Inc. (NASDAQ: ARTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
ARTL
Analyst Actions
- 4/2/24 - HC Wainwright
ARTL
Sec Filings
- 3/29/24 - Form S-8
- 3/25/24 - Form 10-K
- 3/4/24 - Form 8-K
- ARTL's page on the SEC website